Brooks A. Benard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Brooks A. Benard has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Thomas
School of Medicine, College of Health, Adelaide University, Adelaide, Australia
67 shared publications - Richard J. D'ANdrea
Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, Australia
66 shared publications - Saumya E. Samaraweera
Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australia
66 shared publications - Andy G. X. Zeng
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
64 shared publications - Angel F. Lopez
Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia
64 shared publications - C. Glenn Begley
11Begley Biotech Consulting, Wallington, Victoria, Australia
64 shared publications
Latest Publications
- Open Access
Mouse lymph node colonization models predict human tumor metastasis in melanoma
Aggressive tumor progression and distant metastases of cancers such as cutaneous melanoma are thought to be preceded by regional lymph node (LN) infiltration. Previous mouse studies have selectively enriched for tumor cells with enhanced LN migratory capacity but the mechanistic biology underpinning this proclivity has not been directly linked to human outcomes. Likewise, the exact role LN colonization plays in distant metastasis in humans remains unclear. To translate and conserve findings from mouse models to humans, we used a computational framework termed Translatable Components Regression (TransComp-R) to integrate mouse LN tumor samples with human primary and metastatic tumors. We identified transcriptional programs of early- and late-stage mouse tumor generations that stratified primary and metastatic tumors from patients with melanoma. These transcriptional programs associated with immune function, cell cycle checkpoints, and DNA-to-protein biosynthesis pathways. We then employed EcoTyper and identified six distinct melanoma-specific cellular communities (ecotypes) comprising co-occurring cell states. Of these six melanoma ecotypes, we identified a community strongly associated with primary tumor cells, while the other five represented a spectrum of metastatic tumor microenvironments with increased adverse outcomes. These ecotypes and their significantly expressed genes may contribute to the tumor-immune microenvironment that facilitates LN colonization in melanoma. We further validated the physical co-localization of these melanoma ecotypes using spatial transcriptomics. Our integration of pre-clinical models with human data reveals potential biological pathways and transcriptomic signatures for future investigation and supports the utility of mouse models in studying cancer metastasis. GRAPHICAL
Open AccessMouse lymph node colonization models predict human tumor metastasis in melanoma
Aggressive tumor progression and distant metastases of cancers such as cutaneous melanoma are thought to be preceded by regional lymph node (LN) infiltration. Previous mouse studies have selectively enriched for tumor cells with enhanced LN migratory capacity but the mechanistic biology underpinning this proclivity has not been directly linked to human outcomes. Likewise, the exact role LN colonization plays in distant metastasis in humans remains unclear. To translate and conserve findings from mouse models to humans, we used a computational framework termed Translatable Components Regression (TransComp-R) to integrate mouse LN tumor samples with human primary and metastatic tumors. We identified transcriptional programs of early- and late-stage mouse tumor generations that stratified primary and metastatic tumors from patients with melanoma. These transcriptional programs associated with immune function, cell cycle checkpoints, and DNA-to-protein biosynthesis pathways. We then employed EcoTyper and identified six distinct melanoma-specific cellular communities (ecotypes) comprising co-occurring cell states. Of these six melanoma ecotypes, we identified a community strongly associated with primary tumor cells, while the other five represented a spectrum of metastatic tumor microenvironments with increased adverse outcomes. These ecotypes and their significantly expressed genes may contribute to the tumor-immune microenvironment that facilitates LN colonization in melanoma. We further validated the physical co-localization of these melanoma ecotypes using spatial transcriptomics. Our integration of pre-clinical models with human data reveals potential biological pathways and transcriptomic signatures for future investigation and supports the utility of mouse models in studying cancer metastasis. GRAPHICAL
- Open Access
PhenoMapR: scalable mapping of sample phenotypes to single-cell, spatial, and bulk transcriptomics data
Single-cell and spatial transcriptomic studies often lack sufficient sample size to compute robust statistical associations between a sample-level phenotype and cell types or spatial locations. In contrast, lower resolution methods such as bulk gene expression profiling have been applied at scale in large, annotated datasets, providing reliable signatures for phenotype associations. We introduce PhenoMapR, a semi-supervised method designed to integrate the phenotypic rigor of large-scale bulk expression studies with the cellular and spatial granularity of single-cell and spatial transcriptomics. PhenoMapR achieves this by deriving and mapping bulk gene expression signatures onto cells and spatial locations in a computationally efficient and scalable manner. The framework is broadly applicable across biological contexts, supporting the mapping of binary, continuous, and survival phenotypes derived from bulk expression studies across transcriptomic data modalities. This enables the identification of biologically-relevant cellular populations and spatial niches for experimental validation and therapeutic intervention.
Open AccessPhenoMapR: scalable mapping of sample phenotypes to single-cell, spatial, and bulk transcriptomics data
Single-cell and spatial transcriptomic studies often lack sufficient sample size to compute robust statistical associations between a sample-level phenotype and cell types or spatial locations. In contrast, lower resolution methods such as bulk gene expression profiling have been applied at scale in large, annotated datasets, providing reliable signatures for phenotype associations. We introduce PhenoMapR, a semi-supervised method designed to integrate the phenotypic rigor of large-scale bulk expression studies with the cellular and spatial granularity of single-cell and spatial transcriptomics. PhenoMapR achieves this by deriving and mapping bulk gene expression signatures onto cells and spatial locations in a computationally efficient and scalable manner. The framework is broadly applicable across biological contexts, supporting the mapping of binary, continuous, and survival phenotypes derived from bulk expression studies across transcriptomic data modalities. This enables the identification of biologically-relevant cellular populations and spatial niches for experimental validation and therapeutic intervention.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Data from Intra-Leukemic Interferon Signaling Suppresses Expansion and Mediates Chemoresistance in Human AML
Intratumoral heterogeneity can affect the competitive fitness and chemoresistance of individual cancer cells. In acute myeloid leukemia (AML), both genetic and functional heterogeneity contribute to chemoresistance, resulting in relapse. Whereas the role of cell-extrinsic factors has been described for AML relapse, whether interactions between cancer cells affect chemoresistance is not fully known. In this study, we demonstrated that a dominant leukemic fraction can suppress the proliferation and expansion of other leukemic cells and that this suppression is reversible. This suppression is mediated in part by both type I and type II intra-leukemic interferon signaling and dependent on BST2. Importantly, blocking antibodies to type II interferon receptor activated the cycling of this suppressed cell fraction and sensitized the cells to subsequent chemotherapy treatment. Our findings suggest that interactions between functionally heterogeneous leukemic fractions can affect competitive fitness and treatment response, highlighting interferon signaling as a potential therapeutic target to counter chemoresistance.Significance:AML presents a significant challenge in clinical management due to its poor prognosis and high rates of relapse following chemotherapy. Using multiple models of primary human AML, we demonstrate that competitive interactions between leukemia cells affect clonal dynamics and therapy resistance, thereby identifying a potential strategy to improve patient outcomes.See related commentary by Papaioannou and Aifantis, p. 18
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Intra-Leukemic Interferon Signaling Suppresses Expansion and Mediates Chemoresistance in Human AML
Intratumoral heterogeneity can affect the competitive fitness and chemoresistance of individual cancer cells. In acute myeloid leukemia (AML), both genetic and functional heterogeneity contribute to chemoresistance, resulting in relapse. Whereas the role of cell-extrinsic factors has been described for AML relapse, whether interactions between cancer cells affect chemoresistance is not fully known. In this study, we demonstrated that a dominant leukemic fraction can suppress the proliferation and expansion of other leukemic cells and that this suppression is reversible. This suppression is mediated in part by both type I and type II intra-leukemic interferon signaling and dependent on BST2. Importantly, blocking antibodies to type II interferon receptor activated the cycling of this suppressed cell fraction and sensitized the cells to subsequent chemotherapy treatment. Our findings suggest that interactions between functionally heterogeneous leukemic fractions can affect competitive fitness and treatment response, highlighting interferon signaling as a potential therapeutic target to counter chemoresistance.Significance:AML presents a significant challenge in clinical management due to its poor prognosis and high rates of relapse following chemotherapy. Using multiple models of primary human AML, we demonstrate that competitive interactions between leukemia cells affect clonal dynamics and therapy resistance, thereby identifying a potential strategy to improve patient outcomes.See related commentary by Papaioannou and Aifantis, p. 18
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1-S4 from Intra-Leukemic Interferon Signaling Suppresses Expansion and Mediates Chemoresistance in Human AML
Supplementary Table 1 shows List of genes for gene set enrichment analysis Supplementary Table 2 shows Sequences of gRNA Supplementary Table 3 shows List of antibody Supplementary Table 4 shows Sequences of primers and probes
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1-S4 from Intra-Leukemic Interferon Signaling Suppresses Expansion and Mediates Chemoresistance in Human AML
Supplementary Table 1 shows List of genes for gene set enrichment analysis Supplementary Table 2 shows Sequences of gRNA Supplementary Table 3 shows List of antibody Supplementary Table 4 shows Sequences of primers and probes
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-S8 from Intra-Leukemic Interferon Signaling Suppresses Expansion and Mediates Chemoresistance in Human AML
Supplementary Figure 1 shows Suppressed leukemia cells maintain disease-initiating capacity. Supplementary Figure 2 shows iAML isogenic competition model with fluorescent G0 reporter. Supplementary Figure 3 shows Oxidative phosphorylation does not account for suppression Supplementary Figure 4 shows IFN signaling inhibits suppressed samples Supplementary Figure 5 shows BST2 contributes to IFN-mediated AML suppression. Supplementary Figure 6 shows IFN signaling is associated with chemoresistance in experimental models. Supplementary Figure 7 shows IFN signaling is associated with chemoresistance in primary AML patient samples. Supplementary Figure 8 shows Blocking IFN signaling affects cycling and chimerism of patient samples.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-S8 from Intra-Leukemic Interferon Signaling Suppresses Expansion and Mediates Chemoresistance in Human AML
Supplementary Figure 1 shows Suppressed leukemia cells maintain disease-initiating capacity. Supplementary Figure 2 shows iAML isogenic competition model with fluorescent G0 reporter. Supplementary Figure 3 shows Oxidative phosphorylation does not account for suppression Supplementary Figure 4 shows IFN signaling inhibits suppressed samples Supplementary Figure 5 shows BST2 contributes to IFN-mediated AML suppression. Supplementary Figure 6 shows IFN signaling is associated with chemoresistance in experimental models. Supplementary Figure 7 shows IFN signaling is associated with chemoresistance in primary AML patient samples. Supplementary Figure 8 shows Blocking IFN signaling affects cycling and chimerism of patient samples.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
IL3Rα P248 at the IL-3R assembly interface is critical for cell differentiation.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
IL3Rα P248 at the IL-3R assembly interface is critical for cell differentiation.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Summary of the key interactions in the IL-3R ternary complex in the IL-3R ternary complex crystal structure.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Summary of the key interactions in the IL-3R ternary complex in the IL-3R ternary complex crystal structure.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
The IL-3R dodecamer activates STAT1 to induce cell differentiation.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
The IL-3R dodecamer activates STAT1 to induce cell differentiation.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Key interactions between distinct residues in the IL-3R ternary complex crystal structure.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Key interactions between distinct residues in the IL-3R ternary complex crystal structure.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Enrichment of the IL-3R hexamer versus dodecamer gene signature in primitive normal and leukemic stem cells.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Enrichment of the IL-3R hexamer versus dodecamer gene signature in primitive normal and leukemic stem cells.